Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand
Open Access
- 28 May 2020
- journal article
- research article
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 98 (7) , 467-474
Abstract
To assess sales of anti-cancer medicines in the 2017 World Health Organization’s WHO Model list of essential medicines in China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand from 2007 (2008 for Kazakhstan and Malaysia) to 2017. We extracted sales volume data for 39 anti-cancer medicines from the IQVIA database. We divided the total quantity sold by the reference defined daily dose to estimate the total number of defined daily doses sold, per country per year, for three types of anti-cancer therapies (traditional chemotherapy, targeted therapy and endocrine therapy). We adjusted these data by the number of new cancer cases in each country for each year. We observed an increase in sales across all types of anti-cancer therapies in all countries. The largest number of defined daily doses of traditional chemotherapy per new cancer case was sold in Thailand; however, the largest relative increase per new cancer case occurred in Indonesia (9.48-fold). The largest absolute and relative increases in sales of defined daily doses of targeted therapies per new cancer case occurred in Kazakhstan. Malaysia sold the largest number of adjusted defined daily doses of endocrine therapies in 2017, while China and Indonesia more than doubled their adjusted sales volumes between 2007 and 2017. The use of sales data can fill an important knowledge gap in the use of anti-cancer medicines, particularly during periods of insurance coverage expansion. Combined with other data, sales volume data can help to monitor efforts to improve equitable access to essential medicines.Keywords
This publication has 23 references indexed in Scilit:
- Essential medicines for universal health coverageThe Lancet, 2017
- Essential medicines for cancer: WHO recommendations and national prioritiesBulletin of the World Health Organization, 2016
- Essential medicines for breast cancer in low and middle income countriesBMC Cancer, 2015
- Policies and Programs to Facilitate Access to Targeted Cancer Therapies in ThailandPLOS ONE, 2015
- Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in MalaysiaAsian Pacific Journal of Cancer Prevention, 2014
- Influence of Payer Source on Treatment and Outcomes in Colorectal Cancer Patients in a University Hospital in ThailandAsian Pacific Journal of Cancer Prevention, 2014
- Closing the global cancer divide- performance of breast cancer care services in a middle income developing countryBMC Cancer, 2014
- Selection of oncology medicines in low- and middle-income countriesAnnals of Oncology, 2014
- Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series studyBMJ Open, 2012
- Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessabilityLeukemia & Lymphoma, 2012